↓ Skip to main content

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

Overview of attention for article published in this source, October 2013
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
Published by
John Wiley & Sons, Ltd, October 2013
DOI 10.1002/14651858.cd010482.pub2
Pubmed ID
Authors

Lawrie, Theresa A, Rabbie, Roy, Thoma, Clemens, Morrison, Jo

Abstract

Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management. Currently, the recommended standard first-line chemotherapy is platinum-based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non-modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression-free survival compared with PAC/carbo in women with relapsed, platinum-sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first-line setting.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 25%
Canada 1 13%
Unknown 5 63%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 163%
Student > Bachelor 13 163%
Researcher 12 150%
Unspecified 11 138%
Student > Ph. D. Student 10 125%
Other 14 175%
Readers by discipline Count As %
Medicine and Dentistry 35 438%
Unspecified 13 163%
Pharmacology, Toxicology and Pharmaceutical Science 5 63%
Nursing and Health Professions 5 63%
Agricultural and Biological Sciences 4 50%
Other 11 138%